Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia

Concurrent BTK and BCL2 inhibition has not been investigated in Waldenström macroglobulinemia. We performed an investigator-initiated trial of ibrutinib and venetoclax in symptomatic, treatment-naive patients with MYD88-mutated WM. Patients received ibrutinib 420 mg once daily (cycle 1), followed by a ramp-up of venetoclax to 400 mg daily (cycle 2). The combination was then administered for 22 additional four-week cycles. Attainment of VGPR was the primary endpoint. Forty-five patients …